Sionna Therapeutics (SION) announced initiation of the PreciSION CF Phase 2a proof-of-concept trial evaluating SION-719, a first-in-class nucleotide binding domain 1 stabilizer, when added to Trikafta, the current standard of care in CF.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SION:
- Sionna Therapeutics initiated with a Buy at Freedom Capital
- Sionna Therapeutics appoints Caroline Stark Beer as CBO
- Sionna Therapeutics initiated with a Buy at JonesResearch
- Buy Rating for Sionna Therapeutics: Innovative Cystic Fibrosis Treatments with Promising Clinical Trials
- Short Report: Frontier Group short positioning continues gaining altitude